DRUG NAME: Oxaliplatin

SYNONYM(S): ACT-078, I-OHP, LOHP, oxalatoplatin, oxaliplatinum

COMMON TRADE NAME(S): ELOXATIN®

CLASSIFICATION: Alkylating agent

Special pediatric considerations are noted when applicable, otherwise adult provisions apply.

MECHANISM OF ACTION:

Oxaliplatin belongs to a new class of platinum agent. It contains a platinum atom complexed with oxalate and diaminocyclohexane (DACH). The bulky DACH is thought to contribute greater cytotoxicity than cisplatin and carboplatin. The exact mechanism of action of oxaliplatin is not known. Oxaliplatin forms reactive platinum complexes which are believed to inhibit DNA synthesis by forming interstrand and intrastrand cross-linking of DNA molecules. Oxaliplatin is not generally cross-resistant to cisplatin or carboplatin, possibly due to the DACH group and resistance to DNA mismatch repair. Preclinical studies have shown oxaliplatin to be synergistic with fluorouracil and SN-38, the active metabolite of irinotecan. Oxaliplatin is a radiation-sensitizing agent. It is cell cycle phase-nonspecific.

PHARMACOKINETICS:

<table>
<thead>
<tr>
<th>Interpatient variability</th>
<th>inter- and intra-subject variability is low</th>
</tr>
</thead>
<tbody>
<tr>
<td>Distribution</td>
<td>minimal in plasma; accumulation in erythrocytes does not diffuse into plasma or act as a drug reservoir</td>
</tr>
<tr>
<td></td>
<td>cross blood brain barrier?</td>
</tr>
<tr>
<td></td>
<td>volume of distribution</td>
</tr>
<tr>
<td></td>
<td>plasma protein binding</td>
</tr>
<tr>
<td>Metabolism</td>
<td>rapid nonenzymatic biotransformation to reactive platinum complexes</td>
</tr>
<tr>
<td></td>
<td>active metabolite(s)</td>
</tr>
<tr>
<td></td>
<td>inactive metabolite(s)</td>
</tr>
<tr>
<td>Excretion</td>
<td>platinum is mainly by renal excretion and tissue distribution, while platinum metabolites are mainly by renal excretion</td>
</tr>
<tr>
<td></td>
<td>urine</td>
</tr>
<tr>
<td></td>
<td>feces</td>
</tr>
<tr>
<td></td>
<td>terminal half life</td>
</tr>
<tr>
<td></td>
<td>clearance</td>
</tr>
</tbody>
</table>

Adapted from reference unless specified otherwise.

*Ultrafilterable platinum consists of oxaliplatin and free oxaliplatin metabolites.
### USES:

**Primary uses:**
- Colorectal cancer

**Other uses:**
- Breast cancer
- Gastric cancer
- Germ cell cancer
- Head and neck cancer
- Lung cancer, non-small cell
- Lymphoma, non-Hodgkin’s
- Mesothelioma
- Ovarian cancer
- Pancreatic cancer
- Prostate cancer

*Health Canada Therapeutic Products Programme approved indication

No pediatric indications.

### SPECIAL PRECAUTIONS:

#### Contraindications:
- History of hypersensitivity reaction to oxaliplatin or other platinum agents (eg, cisplatin, carboplatin)
- Peripheral sensory neuropathy interfering with function or severe renal dysfunction (CrCl < 30 mL/min)

#### Caution:
- QT prolongation and torsades de pointes are reported; use caution in patients with history of QT prolongation or cardiac disease and those receiving concurrent therapy with other QT prolonging medications. Correct electrolyte disturbances prior to treatment and monitor periodically.

#### Special populations:
- Elderly patients over 65 may be at higher risk of severe (grades 3-4) diarrhea.
- Women may be at higher risk of severe (grades 3-4) neutropenia.

#### Carcinogenicity:
Oxaliplatin is considered a probable carcinogen, although carcinogenic studies have not been done.

#### Mutagenicity:
Mutagenic in mammalian in vitro mutation chromosome tests.

#### Fertility:
No information found.

#### Pregnancy:
Oxaliplatin produced embryo-fetal toxicity in rats.

#### Breastfeeding:
is not recommended due to the potential secretion into breast milk.

### SIDE EFFECTS:

The table includes adverse events that presented during drug treatment but may not necessarily have a causal relationship with the drug. Because clinical trials are conducted under very specific conditions, the adverse event rates observed may not reflect the rates observed in clinical practice. Adverse events are generally included if they were reported in more than 1% of patients in the product monograph or pivotal trials, and/or determined to be clinically important. Incidences of adverse events are generally similar when oxaliplatin is used as a single agent or in combination with fluorouracil and leucovorin, although severe (grades 3-4) diarrhea, nausea and vomiting, and neurotoxicity are more common with combination therapy.
<table>
<thead>
<tr>
<th>ORGAN SITE</th>
<th>SIDE EFFECT</th>
</tr>
</thead>
<tbody>
<tr>
<td>allergy/immunology</td>
<td>anaphylaxis (0.5-2%)&lt;sup&gt;6,28,29&lt;/sup&gt;</td>
</tr>
<tr>
<td>blood/bone marrow</td>
<td>anemia (64-83%, severe 4-5%)</td>
</tr>
<tr>
<td>febrile neutropenia</td>
<td>febrile neutropenia (&lt; 2%)</td>
</tr>
<tr>
<td></td>
<td>immune hemolytic anemia (rare)&lt;sup&gt;30&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>neutropenia: single agent (15%, severe 3%); with fluorouracil and leucovorin (66%, severe 38%)</td>
</tr>
<tr>
<td></td>
<td>thrombocytopenia: single agent (41%, severe 3%); with fluorouracil and leucovorin (76%, severe 4%)</td>
</tr>
<tr>
<td>constitutional symptoms</td>
<td>fever (36%)</td>
</tr>
<tr>
<td>dermatology/skin</td>
<td>extravasation hazard: irritant&lt;sup&gt;31-36&lt;/sup&gt;; treat as vesicant&lt;sup&gt;37&lt;/sup&gt;; see paragraph following Side Effects table</td>
</tr>
<tr>
<td></td>
<td>alopecia (2%)</td>
</tr>
<tr>
<td>gastrointestinal</td>
<td>emetogenic potential: high moderate&lt;sup&gt;38&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>diarrhea: single agent (41%, severe 5%); with fluorouracil and leucovorin (58%, severe 10%)</td>
</tr>
<tr>
<td></td>
<td>mucositis: single agent (4%, severe 2%); with fluorouracil and leucovorin (42%, severe 8%)</td>
</tr>
<tr>
<td></td>
<td>nausea, vomiting (69-71%, severe 12-14%)</td>
</tr>
<tr>
<td>hepatic</td>
<td>liver function abnormalities (46%, severe 12%)</td>
</tr>
<tr>
<td>infection</td>
<td>infection (23%)</td>
</tr>
<tr>
<td>investigations</td>
<td>QT prolongation, torsades de pointes&lt;sup&gt;25,26,39,40&lt;/sup&gt;</td>
</tr>
<tr>
<td>neurology</td>
<td>central neurotoxicity/reversible posterior leukoencephalopathy syndrome (&lt;1%)&lt;sup&gt;41-45&lt;/sup&gt;; see paragraph following Side Effects table</td>
</tr>
<tr>
<td></td>
<td>neuropathy, sensory (85-95%); see paragraph following Side Effects table</td>
</tr>
<tr>
<td></td>
<td>pharyngolaryngeal dysesthesia (1-2%); see paragraph following Side Effects table</td>
</tr>
<tr>
<td>renal/genitourinary</td>
<td>renal dysfunction (3%, severe &lt; 1%)</td>
</tr>
<tr>
<td>vascular</td>
<td>thromboembolic events, including deep vein thrombosis&lt;sup&gt;46&lt;/sup&gt; (1-10%)&lt;sup&gt;46-48&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

Adapted from reference<sup>6</sup> unless otherwise specified.

**Peripheral sensory neuropathy** is cumulative, dose-related and usually reversible a few months after stopping treatment. Symptoms include sensory ataxia and dysesthesia of the limbs, mouth, throat and larynx, and may be exacerbated by exposure to cold (eg, touching cold surface, drinking cold liquid).<sup>1,38</sup> The incidence of grade 2 neuropathy is 10% after 3 treatment cycles and 50% after 10 cycles. Grade 3 neuropathy occurs in 10% after 9 cycles and 50% after 14 cycles, is reversible in 74% of the cases, and begins to recover after 13 weeks. Paresthesia interfering with function (eg, buttoning clothing, holding objects, writing) is seen in 16% of patients after 4 months of treatment and rarely leads to oxaliplatin withdrawal.<sup>11</sup> Unlike cisplatin, oxaliplatin neuropathy is related to injury to small rather than large sensory fibres.<sup>17</sup> The use of calcium gluconate or magnesium sulfate infusions pre- and/or post oxaliplatin treatment do not appear to reduce or protect against oxaliplatin-induced neurotoxicity.<sup>39-52</sup>

Gabapentin PO 100 mg twice daily, with increments of 100 mg PO daily as needed, may be effective in some patients to reduce oxaliplatin neuropathy.<sup>53</sup> While carbamazepine does not appear to be effective.<sup>54</sup> Other agents used with some success include alpha-lipoic acid IV 600 mg weekly for 3-5 weeks, then followed by oral 600 mg three times daily.<sup>55</sup> Oxaliplatin delivered according to 24-hour biologic rhythms (chronomodulated) appears to be associated with less peripheral neuropathy than fixed rate infusion.<sup>1,12</sup>

**Pharyngolaryngeal dysesthesia** with sporadic reduced sensitivity of the larynx and pharynx is seen in 1-2% of patients shortly after drug infusion. Symptoms usually resolve within hours of onset but the feeling of difficulty in breathing or swallowing may be distressing to the patient. Treatment is usually not needed.
although antihistamines and bronchodilators have been used. To prevent recurrence, infusion time should be extended to 6 hours with subsequent treatments.\textsuperscript{1,6}

**Reversible posterior leukoencephalopathy syndrome** (RPLS; also known as PRES) has been associated with oxaliplatin,\textsuperscript{41-45} which may cause endothelial dysfunction and lead to vasogenic edema.\textsuperscript{42,43} Clinical presentation includes altered mental status, seizures, headache, and loss of vision with associated radiographic abnormality on MRI or CT.\textsuperscript{42} Symptom onset may be delayed relative to treatment, with cases reported 8 to 12 days after the first infusion and as long as 6 weeks post treatment.\textsuperscript{43,44,56} Management is usually supportive, with control of hypertension, electrolyte replacement, seizure management, and discontinuation of oxaliplatin.\textsuperscript{42,43} Although usually reversible, permanent disability and fatalities have been reported.\textsuperscript{42,43}

**Management of extravasation:** Extravasation of oxaliplatin may sometimes cause severe local inflammation and potentially tissue necrosis.\textsuperscript{31-36} The optimal non-pharmacological management of oxaliplatin extravasation is unclear. However, it has been suggested that warm compresses may be preferred over cool compresses\textsuperscript{33,57,58} which may theoretically precipitate or worsen peripheral sensory neuropathy. For management of extravasation reactions, see BCCA Policy Number III-20 *Prevention and Management of Extravasation of Chemotherapy.*

**INTERACTIONS:**

<table>
<thead>
<tr>
<th>AGENT</th>
<th>EFFECT</th>
<th>MECHANISM</th>
<th>MANAGEMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>fluorouracil\textsuperscript{59}</td>
<td>no influence on fluorouracil pharmacokinetics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>irinotecan\textsuperscript{60-62}</td>
<td>induction of irinotecan-related cholinergic syndrome</td>
<td>may potentiate irinotecan inhibition of acetylcholinesterase</td>
<td>give prophylactic atropine before irinotecan</td>
</tr>
<tr>
<td>topotecan\textsuperscript{63}</td>
<td>no effects on topotecan pharmacokinetics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>warfarin\textsuperscript{64}</td>
<td>significantly higher incidence of INR elevation when administered with oxaliplatin/fluorouracil based regimens</td>
<td>unknown; possible synergy of anticoagulant effect of fluorouracil by oxaliplatin</td>
<td>for oxaliplatin/fluorouracil based regimens only: monitor INR regularly during and for one month following completion of treatment; adjust warfarin dose as needed</td>
</tr>
</tbody>
</table>

Avoid concurrent use of QT/QTc-prolonging drugs if possible. Use caution with drugs that may disrupt electrolyte levels. Correct electrolytes as needed and monitor as applicable.\textsuperscript{25}

**SUPPLY AND STORAGE:**

*Injection:* sanofi-aventis Canada Inc. supplies oxaliplatin as 50 mg and 100 mg single-use vials of sterile lyophilized powder and 50 mg, 100 mg, and 200 mg single-use vials of sterile preservative-free aqueous solution in a concentration of 5 mg/mL. Store at room temperature. Do not freeze. Protect from light for long-term storage.\textsuperscript{45}

*For basic information on the current brand used at the BC Cancer Agency, see Chemotherapy Preparation and Stability Chart in Appendix.*

**SOLUTION PREPARATION AND COMPATIBILITY:**

*For basic information on the current brand used at the BC Cancer Agency, see Chemotherapy Preparation and Stability Chart in Appendix.*
**Additional information:**

- Aluminum-containing IV needles, syringes or sets should not be used to prepare or administer oxaliplatin; aluminum reacts with platinum from oxaliplatin to form a precipitate, resulting in loss of potency.6
- Oxaliplatin can be co-administered with leucovorin infusion using a Y-line placed immediately before the site of injection; however, the drugs should not be combined in the same infusion bag.65,66

**Compatibility:** consult detailed reference

**PARENTERAL ADMINISTRATION:**

| Subcutaneous | no information found |
| Intramuscular | no information found |
| Direct intravenous | no information found |
| Intermittent infusion | • *in 500 mL D5W over 2 h*11;  
• *in 250-500 mL D5W over 30 min*9, 3 h67, or 6 h12;  
• administer before fluoropyrimidines (eg, fluorouracil)6;  
• do not piggyback or flush lines with sodium chloride solution6 |
| Continuous infusion | chronomodulated infusion over 5 days using programmable-in-time pump12 |
| Intraperitoneal | hyperthermic intraperitoneal chemotherapy (HIPEC): pump solution into abdominal cavity and circulate as per protocol using hyperthermia pump; solutions and dwell time vary by protocol66-70 |
| Intrapleural | no information found |
| Intrathecal | no information found |
| Intra-arterial | investigational, over 4 h71 |
| Intravesical | no information found |

**DOSAGE GUIDELINES:**

Refer to protocol by which patient is being treated. Numerous dosing schedules exist and depend on disease, response and concomitant therapy. Guidelines for dosing also include consideration of absolute neutrophil count (ANC). Dosage may be reduced, delayed or discontinued in patients with bone marrow depression due to cytotoxic/radiation therapy or in patients with other toxicities.

**Adults:**

**Intravenous:**

- **Cycle Length:**
  - 1 week: 35 mg/m² IV for one dose on day 1
  - 2 weeks: 85 mg/m² (range 80-100 mg/m²) IV for one dose on day 1
  - 3 weeks: 130 mg/m² (range 85-135 mg/m²) IV for one dose on day 1
  - 4 weeks: 30 mg/m²/day by continuous IV infusion for 5 consecutive days
    (total dose per cycle 150 mg/m²)73
  - 35 mg/m²/day by chronomodulated IV infusion for 5 consecutive days
    (total dose per cycle 175 mg/m²)73

- **BCCA usual dose noted in bold, italics**
50 days: 50 mg/m² IV for one dose on days 1, 8, 15, 22, 29, 36 (total dose per cycle 300 mg/m²)

Concurrent radiation: investigational, 130 mg/m² IV on days 1 and 29 concurrent with radiation

Dosage in myelosuppression: modify according to protocol by which patient is being treated; if no guidelines available, refer to Appendix 6 “Dosage Modification for Myelosuppression”

Dosage in neurotoxicity:

<table>
<thead>
<tr>
<th>Duration of Neurotoxicity</th>
<th>Severity</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt; 7 days&lt;sup&gt;6,11&lt;/sup&gt;</td>
<td>troublesome</td>
<td>reduce dose from: 130 mg/m² to 100 mg/m²; or from 85 mg/m² to 65 mg/m²; or from 65 mg/m² to 50 mg/m²</td>
</tr>
<tr>
<td>persists until next cycle&lt;sup&gt;6&lt;/sup&gt;</td>
<td>no functional impairment</td>
<td>reduce dose from 85 mg/m² to 65 mg/m²</td>
</tr>
<tr>
<td>&gt; 7 days&lt;sup&gt;11&lt;/sup&gt;</td>
<td>functional impairment</td>
<td>reduce dose from 85 mg/m² to 50 mg/m²</td>
</tr>
<tr>
<td>persists until next cycle&lt;sup&gt;6,11&lt;/sup&gt;</td>
<td>functional impairment</td>
<td>discontinue*</td>
</tr>
</tbody>
</table>

*if neurotoxicity improves following discontinuation, resumption of therapy may be considered<sup>5,76</sup>

Dosage in renal failure:

<table>
<thead>
<tr>
<th>CrCl (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt; 30</td>
<td>100%&lt;sup&gt;11&lt;/sup&gt;</td>
</tr>
<tr>
<td>&lt; 30</td>
<td>no information found</td>
</tr>
</tbody>
</table>

CrCl (mL/min) = \( N \times (140 - \text{Age}) \times \text{wt (kg)} \)

where N = 1.04 for females and 1.23 for males

Dosage in hepatic failure: no adjustment required for mild to moderate liver dysfunction<sup>5</sup>; no information found regarding severe hepatic insufficiency

Dosage in dialysis: no information found

Children: has been used; effectiveness has not been established<sup>45</sup>

REFERENCES:

25. sanofi-aventis Canada Inc. ELOXATIN® product monograph. Laval, Quebec; 13 March 2015.


45. sanofi-aventis Canada Inc. ELOXATIN® product monograph. Laval, Quebec; 17 September 2010.

46. sanofi-aventis Canada Inc. ELOXATIN® product monograph. Laval, Quebec; 8 June 2011.


